



Lausanne, 19.11.2010

## Company Communication

# EuroNanoMed grants €1.5 million for Hepatitis C vaccine development using Medipol's technology

A project proposal aiming to develop a novel Hepatitis C (HCV) vaccine by using Medipol's technology platform has been accepted by the European funding entity EuroNanoMed. The consortium which will receive a funding exceeding **€ 1.5 million** for three years comprises the Institute for Virology and Immunoprophylaxis in Bern, the Institute Pasteur and the Hôpital Cochin in Paris, the Helmholtz Institute for Infectious Diseases in Braunschweig, EDI GmbH, Reutlingen and Medipol SA.

The goal of the project is to advance Medipol's nanogel technology in combination with an RNA construct towards a vaccine candidate against HCV.

After the EU grant of € 2.5 million for the development of a novel influenza vaccine, the grant constitutes the second major financing to develop Medipol's technology platform for a prophylactic modality.

### About Medipol

Medipol will become a leading fully fledged immunotherapy development company focusing on next generation treatments with broad applications against infectious diseases and cancer. The company applies its proprietary technology platform in conjunction with proteins and RNA constructs to develop vaccines and therapies for unmet medical needs.

### Contact

Medipol SA  
PSE-B  
CH-1015 Lausanne  
T +41 21 693 9031  
F +41 21 693 9032